6 completed. 6 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 2 | 2 | Completed 2 |
Follow Subcutaneous Emphysema: new trials by email Literature Review of Subcutaneous Emphysema trials Research Report on Subcutaneous Emphysema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study GLASSIA - Alpha1-antitrypsin Deficiency | Phase 3 | Completed | Baxalta now part of Shire | 34 | 2016-03-08 | 2021-10-14 |
| Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD) Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP - Pulmonary Emphysema in Alpha-1 PI Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 345 | 2014-04-01 | 2026-10-01 |
| International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema Kamada AAT for inhalation, Placebo - Emphysema | Phase 2 / Phase 3 | Completed | Kamada, Ltd. | 168 | 2009-12-01 | 2019-11-29 |
| Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Kamada-API - Alpha 1-Antitrypsin Deficiency | Phase 2 / Phase 3 | Completed | Kamada, Ltd. | 50 | 2007-03-01 | 2007-10-17 |
| The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency alpha-1 proteinase inhibitor (human) - Alpha 1-Antitrypsin Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 38 | 2006-06-01 | 2014-08-19 |
| Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults Alpha-1 MP, alpha-1 proteinase inhibitor (human) - Alpha 1-Antitrypsin Deficiency | Phase 3 | Completed | Grifols Therapeutics LLC | 24 | 2006-05-01 | 2014-09-09 |
alpha 1-Antitrypsin Deficiency (6) · Pulmonary Emphysema (4) · Emphysema (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Digestive System Diseases (6) · Genetic Diseases, Inborn (6) · Liver Diseases (6) · Lung Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Respiratory Tract Diseases (6) · Emphysema (5) · Chronic Disease (4) · Disease Attributes (4) · Lung Diseases, Obstructive (4) · Pulmonary Disease, Chronic Obstructive (4)
alpha 1-Antitrypsin (4) · Mp alpha1 receptor (2) · Inhalation (1) · Injections (1) · Sodium Chloride (1)
Grifols Therapeutics LLC (3) · Kamada, Ltd. (2) · Baxalta now part of Shire (1)
United States (5) · Canada (3) · Denmark (2) · Germany (2) · Sweden (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Brazil (1) · Estonia (1) · Finland (1) · France (1) · Ireland (1) · Moldova (1) · Netherlands (1)
Kim Hanna, MSc (2) · Jan Stolk, Professor (1) · Robert A Sandhaus, M.D. (1)